The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...

US generic competition for Johnson & Johnson’s (J&J) Zytiga (abiraterone) prostate cancer drug has moved a step closer after a court invalidated a key patent. J&J has said it will appeal against ...

The CAPItello-281 study evaluated the combination of Truqap, J&J’s JNJ Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone ...